Travere Therapeutics/$TVTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Ticker
$TVTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
385
Website
TVTX Metrics
BasicAdvanced
$1.4B
-
-$2.78
0.74
-
Price and volume
Market cap
$1.4B
Beta
0.74
52-week high
$25.29
52-week low
$7.93
Average daily volume
1.5M
Financial strength
Current ratio
2.051
Quick ratio
1.955
Long term debt to equity
993.952
Total debt to equity
1,220.068
Interest coverage (TTM)
-20.03%
Profitability
EBITDA (TTM)
-178.608
Gross margin (TTM)
17.42%
Net profit margin (TTM)
-82.88%
Operating margin (TTM)
-82.29%
Effective tax rate (TTM)
0.01%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
-23.21%
Return on equity (TTM)
-422.66%
Valuation
Price to revenue (TTM)
4.575
Price to book
41.44
Price to tangible book (TTM)
-19.16
Price to free cash flow (TTM)
-4.684
Free cash flow yield (TTM)
-21.35%
Free cash flow per share (TTM)
-327.07%
Growth
Revenue change (TTM)
75.65%
Earnings per share change (TTM)
31.77%
3-year revenue growth (CAGR)
6.17%
10-year revenue growth (CAGR)
19.63%
3-year earnings per share growth (CAGR)
-5.47%
10-year earnings per share growth (CAGR)
32.13%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
Bulls say / Bears say
FILSPARI® (sparsentan) received full FDA approval in September 2024 for the treatment of primary immunoglobulin A nephropathy (IgAN), leading to significant sales growth, with net product sales reaching approximately $50 million in Q4 2024. (biospace.com)
Travere Therapeutics submitted a supplemental New Drug Application (sNDA) to the FDA in March 2025 for FILSPARI® to treat focal segmental glomerulosclerosis (FSGS), potentially expanding its market reach. (globenewswire.com)
The company reported a strong financial position, ending 2024 with approximately $371 million in cash, cash equivalents, and marketable securities, expected to support operations into 2028. (biospace.com)
Travere voluntarily paused enrollment in the Phase 3 HARMONY Study of pegtibatinase in September 2024 due to manufacturing scale-up issues, delaying the program until at least 2026. (investing.com)
Analysts, including H.C. Wainwright, reduced their price targets for Travere's stock following the enrollment pause, reflecting concerns over the delay in pegtibatinase's market entry. (investing.com)
A shareholder alert was issued in October 2024, investigating potential claims against Travere for securities fraud or other unlawful business practices, which could impact investor confidence. (prnewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
TVTX News
AllArticlesVideos
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Accesswire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Travere Therapeutics stock?
Travere Therapeutics (TVTX) has a market cap of $1.4B as of July 28, 2025.
What is the P/E ratio for Travere Therapeutics stock?
The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of July 28, 2025.
Does Travere Therapeutics stock pay dividends?
No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Travere Therapeutics dividend payment date?
Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Travere Therapeutics?
Travere Therapeutics (TVTX) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.